BMY
Market read
BMY accounts for 2.3% of the group's measured movement across 7.5 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.
ARES, BN, APO moved materially before BMY. BMY crossed its material path threshold at 10:05 ET. ABBV, AAMI, ABT followed.
5 of 25 members in Biopharmaceuticals and Care are active. 0 of 8 disclosed connections are confirming.
Invalidation: The live read weakens if participation falls to 8 of 25 members or fewer.
Research brief
BMY accounts for 2.3% of the group's measured movement across 7.5 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“Gains or losses resulting from changes in fair value of the underlying debt attributable to the hedged benchmark interest rate risk are recorded in interest expense with an associated offset to the carrying value of debt.”10-Q · Jul 30, 2026 ↗
“We will disclose any product with levels of inventory in excess of one month on hand or expected demand for the current quarter, subject to certain limited exceptions, in our next quarterly report on Form 10-Q.”10-Q · Jul 30, 2026 ↗
“34 Legacy Portfolio • Eliquis revenues increased 22% during the second quarter of 2026 and 19% year-to-date, primarily due to higher demand, foreign exchange impacts of 1% and 2%, respectively, and higher average net selling prices in the U.S.”10-Q · Jul 30, 2026 ↗
“Selling, General and Administrative Selling, general and administrative expense increased by $113 million in the second quarter of 2026 and $145 million year-to-date, primarily due to higher investments in new product launches, partially offset by cost saving…”10-Q · Jul 30, 2026 ↗
Valuation discipline
Price/sales 2.7× · EV/sales 3.4×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for BMY. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
Jodie has not yet found a suitable current-versus-prior filing comparison for BMY. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“The IDMC recommended that the other two Phase III trials, Librexia AF for patients with atrial fibrillation AF and Librexia STROKE for secondary stroke prevention, continue as planned, with topline data expected in 2026.”
“BioNTech In June 2025, BMS and BioNTech entered into a global strategic collaboration for the co-development and co-commercialization of pumitamig (BNT327/BMS986545), a bispecific antibody targeting PD-L1 and VEGF-A, which is currently being evaluated in a Ph…”
Depended on by
“Our active clinical portfolio includes prasinezumab currently being evaluated in the Phase 3 PARAISO clinical trial for the treatment of early Parkinson’s disease in partnership with Roche, coramitug currently being evaluated in the Phase 3 CLEOPATTRA clinica…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 25 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
BMY is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
No durable theme membership has been observed for this name yet.